Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 1001

Drug Profile

CB 1001

Alternative Names: Cancer vaccine - Cosmo Pharmaceuticals; CB-10-01; TLI

Latest Information Update: 04 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 08 Jul 2009 Phase-II development is ongoing in USA
  • 03 May 2005 Phase-II clinical trials in Prostate cancer in USA (Infusion)
  • 09 Jun 2004 Preclinical trials in Solid tumours in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top